Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) have earned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.13.
Several equities research analysts have commented on the stock. StockNews.com started coverage on shares of Mesoblast in a research report on Thursday, October 5th. They issued a “sell” rating on the stock. William Blair downgraded Mesoblast from an “outperform” rating to a “market perform” rating in a report on Friday, August 4th. Piper Sandler downgraded Mesoblast from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $7.00 to $2.00 in a report on Friday, August 4th. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $17.00 price objective on shares of Mesoblast in a report on Thursday, September 21st.
Hedge Funds Weigh In On Mesoblast
Mesoblast Price Performance
Shares of Mesoblast stock opened at $1.16 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.20. The company’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $2.52. Mesoblast has a 52 week low of $1.12 and a 52 week high of $5.12. The stock has a market cap of $188.89 million, a PE ratio of -2.17 and a beta of 3.39.
Mesoblast (NASDAQ:MESO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Mesoblast had a negative net margin of 1,061.43% and a negative return on equity of 16.32%. The firm had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts anticipate that Mesoblast will post -0.47 EPS for the current fiscal year.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
- Five stocks we like better than Mesoblast
- The 3 Best Fintech Stocks to Buy Now
- Advanced Auto Parts may be worth more in pieces than the whole
- Comparing and Trading High PE Ratio Stocks
- The Trade Desk train returns to the station
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 2 low priced AdTech stocks to ride the advertising rebound
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.